Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT04390399 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

328

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

BIOLOGICAL: N-803
DRUG: Aldoxorubicin HCl
BIOLOGICAL: PD-L1 t-haNK
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Cyclophosphamide
DRUG: 5-Fluorouracil
DRUG: Leucovorin
PROCEDURE: SBRT
DRUG: Irinotecan liposome

Sponsor

ImmunityBio, Inc.